BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 21697278)

  • 1. A novel tumor antigen derived from enhanced degradation of bax protein in human cancers.
    Nunes CT; Miners KL; Dolton G; Pepper C; Fegan C; Mason MD; Man S
    Cancer Res; 2011 Aug; 71(16):5435-44. PubMed ID: 21697278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.
    Maia S; Haining WN; Ansén S; Xia Z; Armstrong SA; Seth NP; Ghia P; den Boer ML; Pieters R; Sallan SE; Nadler LM; Cardoso AA
    Cancer Res; 2005 Nov; 65(21):10050-8. PubMed ID: 16267031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
    Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
    Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
    Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
    Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
    Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
    J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
    Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
    Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.
    Dewson G; Snowden RT; Almond JB; Dyer MJ; Cohen GM
    Oncogene; 2003 May; 22(17):2643-54. PubMed ID: 12730678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.
    Tabarkiewicz J; Giannopoulos K
    Transplant Proc; 2010 Oct; 42(8):3293-6. PubMed ID: 20970674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The modulating effect of proapoptotic protein Bax on the resistance of malignant lymphoma cells to tumor necrosis factor related apoptosis inducing ligand-induced apoptosis].
    Hao JH; Yu M; Jia L; Liu FT; Li Q; Hao XS
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(2):134-7. PubMed ID: 17418025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
    Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
    Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock proteins in antigen trafficking--implications on antigen presentation to T cells.
    Udono H; Ichiyanagi T; Mizukami S; Imai T
    Int J Hyperthermia; 2009 Dec; 25(8):617-25. PubMed ID: 19551545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
    Kim CJ; Parkinson DR; Marincola F
    J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid.
    Poggi A; Venturino C; Catellani S; Clavio M; Miglino M; Gobbi M; Steinle A; Ghia P; Stella S; Caligaris-Cappio F; Zocchi MR
    Cancer Res; 2004 Dec; 64(24):9172-9. PubMed ID: 15604289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
    Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance.
    Thomas A; El Rouby S; Reed JC; Krajewski S; Silber R; Potmesil M; Newcomb EW
    Oncogene; 1996 Mar; 12(5):1055-62. PubMed ID: 8649796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.
    McWhirter JR; Kretz-Rommel A; Saven A; Maruyama T; Potter KN; Mockridge CI; Ravey EP; Qin F; Bowdish KS
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):1041-6. PubMed ID: 16418292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.